ERBB2 and glioma: GD2 is another prevalent antigen target that is highly expressed on glioma cells with the histone H3K27M mutation.87 CAR T cells against the GD2 antigen induced clinical and radiographic improvement in the majority of patients trialed with H3K27M-mutated DMG or spinal cord DMG.88 Toxicities associated with GD2-CAR T cells were tolerable and reversible with supportive treatment.88 Similarly, human epidermal growth factor receptor 2 (HER2)-targeting CAR T cells have shown efficacy, demonstrating antigen-specific cytotoxicity and tumor regression in DMG xenograft models.89,90